Seagen

Youtube Subscribe

Open: 206.0 Close: 206.5 Change: 0.5

The 10 top things that an AI found about Seagen Company Inc Stock and you do not know…

How much time have you spent trying to decide whether investing in Seagen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Seagen are: Seagen, Inc, …

Concept Map

Semantic Network

Stock Summary

Seagen Inc. develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors. It has collaboration agreements with Takeda.

Today's Summary

Pfizer is reportedly in talks to buy the cancer drugmaker. Pfizer reportedly in negotiations to buy Seagen. Seagen currently has a consensus rating of “Hold”

Today's News

Seagen Inc. per Employee $664.01K P/E Ratio N/A Dividend N/a Ex-Dividend Date. Short Interest 6.7M 08/31/23 % of Float Shorted 361%. Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the second quarter ended June 30, 2023. Federal Trade Commission is asking for more information regarding Pfizers planned $43 billion acquisition of Seagen. Seagen and nurix partner to develop new cancer therapy, deal could reach $3.4 billion. Seagen is paying $60 million upfront, and the deal could total up to $3 billion. Whales have been targeting a price range from $155.0 to $210.0 for Seagen over the last 3 months. With a volume of 396,341, the price of SGEN is up 0.47% at $206.91. Pfizer is reportedly in talks to buy the cancer drugmaker. Seagen Inc. latest sec filings for seagen inc. (sgen) Latest SEC filings for Seagen inc.: $206.50 0.56 ( +0.27%) Seagen is where revolutionary science meets transformative cancer therapy. Seagen and Genmab announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone. Seagen (NASDAQ:SGEN – Get Free Report ) last announced its quarterly earnings results on Wednesday, August 2nd. Morgan Stanley reiterated an “equal weight” rating and set a $229.00 price target on shares of Seagen. Seagen currently has a consensus rating of “Hold”

Stock Profile

"Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington."

Keywords

The game is changing. There is a new strategy to evaluate Seagen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Seagen are: Seagen, Inc, cancer, price, result, therapy, deal, and the most common words in the summary are: seagen, job, best, data, stock, inc, clinical, . One of the sentences in the summary was: Seagen currently has a consensus rating of “Hold”. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #seagen #job #best #data #stock #inc #clinical.

Read more →

Youtube Subscribe

---